The development of pharmacological inhibitors of DYRK1A is a major avenue for the treatment of cognitive deficits associated with DS (and Alzheimer’s disease) (reviews: [88,89,93]). This evidence concerns the gene DYRK1A and early-onset autosomal dominant Alzheimer disease.